MetaCap

AbbVie (ABBV) vs Pfizer (PFE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbbVie (ABBV) has outperformed Pfizer (PFE) over the past year, gaining 21.1% versus a gain of 9.4%. Over five years, ABBV leads with a +145.6% price change compared with -49.3% for PFE. AbbVie is the larger company by market cap ($505.89 billion vs $156.18 billion), about 3.2 times the size.

On valuation, Pfizer trades at a lower forward P/E (9.3x vs 17.6x for AbbVie). Pfizer offers the higher dividend yield (7.85% vs 2.42%). Pfizer converts more of its revenue into profit, with a net margin of 12.4% versus 6.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABBV+21.13%PFE+9.42%
+27%+4%-19%
Nov 21, 20251 yearNov 20, 2026
ABBV+146.21%PFE-46.06%
+164%+48%-67%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABBV versus PFE key metrics
MetricABBVPFE
Share price$286.20$27.40
Market cap$505.89B$156.18B
1-day change+0.94%-0.51%
YTD return+25.26%+10.04%
1-year return+21.13%+9.42%
5-year return+145.64%-49.26%
P/E ratio (TTM)49.1839.14
Forward P/E17.659.28
EPS (TTM)$5.82$0.70
Dividend yield2.42%7.85%
Annual dividend$6.92$2.15
Revenue (latest FY)$61.16B$62.58B
Revenue growth (YoY)+8.57%-1.65%
Net income (latest FY)$4.23B$7.77B
Gross margin70.24%74.33%
Operating margin24.65%—
Net margin6.91%12.42%
52-week high$302.93$31.44
52-week low$190.75$23.62
Distance from 52-week high-5.52%-12.85%
Analyst consensusbuybuy
Avg. price target upside+9.76%+10.29%
Average volume4.84M33.52M
Shares outstanding1.77B5.70B
Employees57,00075,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AbbVie is about 3.2 times larger than Pfizer by market value ($505.89B vs $156.18B).
  • ABBV has outperformed PFE by 11.7 percentage points over the past year.
  • AbbVie trades at a higher earnings multiple (49.2x vs 39.1x trailing P/E).
  • Pfizer offers a meaningfully higher dividend yield (7.85% vs 2.42%).
  • Pfizer is more profitable, keeping 12.4 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.
  • AbbVie grew revenue faster in its latest fiscal year (+8.57% vs -1.65%).

About AbbVie

ABBV stock →

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees

About Pfizer

PFE stock →

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees

ABBV vs PFE FAQ

Which is bigger, AbbVie or Pfizer?

AbbVie (ABBV) is larger, with a market capitalization of $505.89B compared with $156.18B for Pfizer (PFE).

Which stock has performed better over the past year, ABBV or PFE?

ABBV returned +21.13% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABBV or PFE?

PFE has the lower trailing P/E at 39.1, versus 49.2 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, AbbVie or Pfizer?

Pfizer has the higher yield at 7.85%, compared with 2.42% for AbbVie.

Are AbbVie and Pfizer in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons